Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis
about
KASL clinical practice guidelines: management of hepatitis CHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionBarriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Overview and recent trends of systematic reviews and meta-analyses in hepatology.Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan ChicagoHepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.Human immunodeficiency virus and liver disease: An update.Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenanceSuccessful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.2013 Update in addiction medicine for the generalist.Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsModels of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study.Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy.Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.Health workers' support for hepatitis C treatment uptake among clients with a history of injecting.
P2860
Q26752471-57B5C56D-92FE-4549-9D46-313FA1B50BC7Q26798469-B19F7E40-B40D-4A24-A8F0-777812B31C8FQ26801456-C17803D9-084A-4FE0-BD00-97AF227946F8Q27010548-71658FD3-AB1A-47D8-B823-4346E4DA2EF5Q30429470-96872083-53F9-43EB-B0A1-CC349CD4E3CDQ30434752-BF46DAB3-1384-47E9-A990-D61B08B5101EQ33821728-99D7124E-48AE-4351-BBBD-DBCAFA94FD1CQ33853664-1A699977-8040-4B11-825B-E24698C6AA06Q34260886-9235D676-2A82-4B8D-8A43-493BE4442556Q35565944-9A0F62EA-2DCD-4E4C-8C64-2A132997F930Q35752296-6ED3FEFD-60F1-4E3C-A9B9-05FF593C7A3DQ35961748-C3DA4427-B9AD-4E61-B9F3-8C7F8DD936E0Q36079786-B4D595AC-7A32-40FD-BBF5-73BDA7C87B8DQ36079814-D30A9FF1-A75F-4FED-8078-5E2EFBA0C113Q36192804-A995947E-4FBF-4248-A4F3-A7C0FE95AA8AQ36319803-1BE0F2ED-306B-4DBC-B510-CC816B22D49FQ36378109-F8EF92B5-EE85-4C41-A301-2BD7E768A291Q36562909-2F0FE52E-40CC-4E43-9DED-ABD6E31495E2Q36802839-8DECFAB3-2043-49A7-B0C1-0AC4F3EA0D3CQ37245420-24656016-6251-467C-AB74-DD8A630417B8Q37284626-0F26067F-A4E2-4054-BE4D-A87C2A95896EQ37358615-8F426A11-043E-4E09-8AEE-31E036A34C82Q37455611-F0F6F444-9AC0-48A8-9A75-B2E746A6E3CDQ37601315-25E88E8D-AE67-4E6D-A899-C829DE673CE4Q38123945-A280C417-C8C1-4537-93D8-82E12F26BAF9Q38123947-C20D489F-46FC-4228-AC5A-703D0157C7C7Q38613271-DE426E07-18AA-4896-B4DC-CE7CDD71E041Q38746105-E76E1125-27D3-46E5-AFEB-22DFD8611AB9Q38907436-EF254D55-7960-42F3-9BA6-2087EF905FB8Q39269740-57FAFEC8-4F91-4908-9211-F51A8808F09FQ40082158-84432269-878C-41AD-B2C4-100284B5ACECQ40167729-439E706C-69B5-4DDF-A8EB-C90186C6918DQ40250921-D050180A-CAFE-4560-A8EC-645B5B2ED859Q40272763-4F45816D-0076-4362-9C61-49DE8331262FQ40565822-17436935-7FF7-477D-A377-577811342A4DQ40565832-6706B8B3-9744-45FC-8F0F-6067643995FFQ40641871-121C0CDB-77A6-44A6-A276-3553AE323EDBQ40652912-9953CCC7-BC67-4BBE-8ADA-452A0CCA608BQ40785885-B0B2BFFF-1CA3-4147-A068-89B432BDBF1FQ40789247-2E27DE03-2ED3-4730-BF71-9BA398370EF8
P2860
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@ast
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@en
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@nl
type
label
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@ast
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@en
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@nl
prefLabel
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@ast
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@en
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@nl
P2093
P2860
P3181
P356
P1476
Determinants of hepatitis C vi ...... sers assessed by meta-analysis
@en
P2093
A. H. Talal
D. C. Des Jarlais
I. M. Jacobson
M. Zeremski
R. B. Dimova
P2860
P304
P3181
P356
10.1093/CID/CIS1007
P407
P577
2013-03-01T00:00:00Z